High relaxivity magnetic resonance imaging contrast agents part 1: Impact of single donor atom substitution on relaxivity of serum albumin-bound gadolinium complexes

Investigative Radiology

Volumn 45, Issue 10, 2010, Pages 600-612

  Dumas, Stéphane ^a   Jacques, Vincent ^a   Sun, Wei Chuan ^a   Troughton, Jeffrey S ^a   Welch, Joel T ^a   Chasse, Jaclyn M ^a   Schmitt Willich, Heribert ^b   Caravan, Peter ^a,c  

^a EPIX Pharmaceuticals   (United States)

^b BAYER PHARMA AG   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

gadolinium; NMRD; protein binding; relaxivity; water exchange

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACETIC ACID; AMIDE; BENZENE DERIVATIVE; CONTRAST MEDIUM; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIC ACID; HETEROCYCLIC COMPOUND; HUMAN SERUM ALBUMIN; HYDROXAMIC ACID; IMIDAZOLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OXYGEN 17; PHOSPHONIC ACID DERIVATIVE; SULFONAMIDE; WATER;

ARTICLE; ATOM; CHEMICAL STRUCTURE; CHIRALITY; COMPLEX FORMATION; CONTRAST ENHANCEMENT; MAGNETIC FIELD; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TEMPERATURE;

EID: 77957275142     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181ee5a9e     Document Type: Article

References (60)

1. Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int. 2007;72:260-264.
2. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
3. Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistri-bution and skin cellularity following a single injection of omniscan in the rat. Invest Radiol. 2010;45:507-512.
4. Aime S, Castelli DD, Crich SG, et al. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. Acc Chem Res. 2009;42:822-831.
5. Major JL, Meade TJ. Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res. 2009;42:893-903.
6. Datta A, Raymond KN. Gd-hydroxypyridinone (HOPO)-based high-relaxiv-ity magnetic resonance imaging (MRI) contrast agents. Acc Chem Res. 2009;42:938-947.
7. Bazeli R, Coutard M, Daumas-Duport B, et al. In vivo evaluation of a new MRI contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol. 2010;45:662-668.
8. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev. 2006;35:512-523.
9. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293-2352.
10. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;1:128-137.
11. Powell DH, Ni Dhubhghaill OM, Pubanz D, et al. Structural and dynamic parameters obtained from 17O NMR, EPR, and NMRD studies of monomeric and dimeric Gd3 + complexes of interest in magnetic resonance imaging: an integrated and theoretically self-consistent approach. J Am Chem Soc. 1996; 118:9333-9346.
12. Caravan P, Astashkin AV, Raitsimring AM. The gadolinium(III)-water hydrogen distance in MRI contrast agents. Inorg Chem. 2003;42:3972-3974.
13. 3+ complexes in glassy solutions. Appl Magn Reson. 2005;28:281-295.
14. Astashkin AV, Raitsimring AM, Caravan P. Pulsed ENDOR study of water coordination to Gd3+ complexes in orientationally disordered systems. J Phys Chem A. 2004;108:1900-2001.
15. Lauffer RB. Targeted relaxation enhancement agents for MRI. Magn Reson Med. 1991;22:339.
16. Benmelouka M, Van Tol J, Borel A, et al. A high-frequency EPR study of frozen solutions of Gd(III) complexes: straightforward determination of the zero-field splitting parameters and simulation of the NMRD profiles. J Am Chem Soc. 2006;128:7807-7816.
17. Borel A, Helm L, Merbach AE, et al. T1e in four Gd3 + chelates: LODEPR measurements and models for electron spin relaxation. J Phys Chem A. 2002;106:6229-6231.
18. Helm L, Merbach AE. Inorganic and bioinorganic solvent exchange mechanisms. Chem Rev. 2005;105:1923-1959.
19. Eldredge HB, Spiller M, Chasse JM, et al. Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol. 2006;41:229-243.
20. Zech SG, Eldredge HB, Lowe MP, et al. Protein binding to lanthanide(III) complexes can reduce the water exchange rate at the lanthanide. Inorg Chem. 2007;46:3576-3584.
21. Caravan P, Parigi G, Chasse JM, et al. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem. 2007;46: 6632-6639.
22. Kruk D, Kowalewski J. Nuclear spin relaxation in paramagnetic systems (S > 1) under fast rotation conditions. JMagn Reson. 2003;162:229-240.
23. Raitsimring AM, Astashkin AV, Baute D, et al. Determination of the hydration number of gadolinium(III) complexes by high-field pulsed (17)O ENDOR spectroscopy. ChemPhysChem. 2006;7:1590-1597.
24. Zech S, Sun WC, Jacques V, et al. Probing the water coordination of protein-targeted MRI contrast agents by pulsed ENDOR spectroscopy. ChemPhysChem. 2005;6:2570-2577.
25. Caravan P, Jacques V, Dumas S, et al; Epix Pharmaceuticals, assignee. Synthesis of high relaxivity chelates for potential use as MRI contrast agents. PCT patent WO2008098056. February 6, 2008.
26. Bannwarth W, Kung E. Bis(allyloxy)(diisopropylamino)phosphine as a new phosphinylation reagent for the phosphorylation of hydroxy functions. Tetrahedron Lett. 1989;30:4219-4222.
27. Bannwarth W, Trzeciak A. A simple and effective chemical phosphorylation procedure for biomolecules. Helv Chim Acta. 1987;70:175-186.
28. Dumas S, Troughton JS, Cloutier NJ, et al. A high relaxivity magnetic resonance imaging contrast agent targeted to serum albumin. Aust J Chem. 2008;61:682-686.
29. Barone AD, Tang JY, Caruthers MH. In situ activation of bis-dialkylamin-ophosphines\a new method for synthesizing deoxyoligonucleotides on polymer supports. Nucleic Acids Res. 1984;12:4051-4061.
30. Eguchi C, Kakuta A. The novel synthesis of L-hydroxyproline from D-glutamic acid. Bull Chem Soc Japan. 1974;47:1704-1708.
31. Schmidt U, Braun C, Sutoris H. Enantioselective syntheses of (R)-and (S)-hexahydropyridazine-3-carboxylic acid derivatives. Synth. 1996;223-229. (Pubitemid 26079457)
32. Koenig SH, Brown RD III. Field-cycling relaxometry of protein solutions and tissue: implications for MRI. Prog Nucl Magn Reson Spectrosc. 1990;22: 487-567.
33. McMurry TJ, Parmelee DJ, Sajiki H, et al. The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. J Med Chem. 2002;45:3465-3474.
34. Li C, Wong WT. A simple, regioselective synthesis of 1,4-bis(tert-butoxy- carbonylmethyl)-tetraazacyclododecane. J Org Chem. 2003;68:2956-2959.
35. Ranganathan RS, Fernandez ME, Kang SI, et al. New multimeric magnetic resonance imaging agents. Invest Radiol. 1998;33:779-797.
36. Aime S, Gianolio E, Terreno E, et al. Ternary Gd(III)L-HSA adducts: evidence for the replacement of inner-sphere water molecules by coordinating groups of the protein. Implications for the design of contrast agents for MRI. J Biol Inorg Chem. 2000;5:488-497.
37. Kalman FK, Woods M, Caravan P, et al. Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH. Inorg Chem. 2007;46:5260-5270.
38. Bloembergen N, Morgan LO. Proton relaxation times in paramagnetic solutions. Effects of electron spin relaxation. J Chem Phys. 1961;34:842-850.
39. Solomon I. Relaxation processes in a system of two spins. Phys Rev. 1955;99:559-565.
40. Lipari G, Szabo A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. J Am Chem Soc. 1982;104:4546-4559.
41. Caravan P, Cloutier NJ, Greenfield MT, et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc. 2002;124:3152-3162.
42. Troughton JS, Greenfield MT, Greenwood JM, et al. Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent. Inorg Chem. 2004;43:6313-6323.
43. Lebduskova P, Hermann P, Helm L, et al. Gadolinium(III) complexes of mono-and diethyl esters of monophosphonic acid analogue of DOTA as potential MRI contrast agents: solution structures and relaxometric studies. Dalton Trans. 2007;493-501.
44. Rudovsky J, Cigler P, Kotek J, et al. Lanthanide(III) complexes of a mono(methylphosphonate) analogue of H4dota: the influence of protonation of the phosphonate moiety on the TSAP/SAP isomer ratio and the water exchange rate. Chem Eur J. 2005;11:2373-2384.
45. Rast S, Fries PH, Belorizky E, et al. A general approach to the electronic spin relaxation of Gd(III) complexes in solutions. Monte Carlo simulations beyond the Redfield limit. J Chem Phys. 2001;115:7554-7563.
46. Caravan P, Farrar CT, Frullano L, et al. Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium-and manganese-based T(1) contrast agents. Contrast Media Mol Imaging. 2009; 4:89-100.
47. Dunand FA, Borel A, Merbach AE. How does internal motion influence the relaxation of the water protons in Ln(III)DOTA-like complexes? J Am Chem Soc. 2002;124:710-716.
48. Yerly F, Borel A, Helm L, et al. MD simulations of acyclic and macrocyclic Gd3 +-based MRI contrast agents: influence of the internal mobility on water proton relaxivity. Chem Eur J. 2003;9:5468-5480.
49. Woods M, Kiefer GE, Bott S, et al. Synthesis, relaxometric andphotophysical properties of a new pH-responsive MRI contrast agent: the effect of other ligating groups on dissociation of a p-nitrophenolic pendant arm. J Am Chem Soc. 2004;126:9248-9256.
50. Andre JP, Toth E, Fischer H, et al. High relaxivity for monomeric Gd-(DOTA)-based MRI contrast agents, thanks to micellar self-organization. Chem Eur J. 1999;5:2977-2983.
51. Lowe MP, Parker D, Reany O, et al. pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. J Am Chem Soc. 2001;123: 7601-7609.
52. Nicolle GM, Toth E, Schmitt-Willich H, et al. The impact of rigidity and water exchange on the relaxivity of a dendritic MRI contrast agent. Chem Eur J. 2002;8:1040-1048.
53. Aime S, Batsanov AS, Botta M, et al. Structure and relaxivity of macrocyclic gadolinium complexes incorporating pyridyl and 4-morpholinopyridyl sub-stituents. New J Chem. 1999;23:669-670.
54. Woods M, Aime S, Botta M, et al. Correlation of water exchange rate with isomeric composition in diastereoisomeric gadolinium complexes of tetra-(carboxyethyl)dota and related macrocyclic ligands. J Am Chem Soc. 2000; 122:9781-9792.
55. Woods M, Botta M, Avedano S, et al. Towards the rational design of MRI contrast agents: a practical approach to the synthesis of gadolinium complexes that exhibit optimal water exchange. Dalton Trans. 2005;3829-3837.
56. Woods M, Kovacs Z, Zhang S, et al. Towards the rational design of magnetic resonance imaging contrast agents: isolation of the two coordination isomers of lanthanide DOTA-type complexes. Angew Chem Int Ed Engl. 2003;42: 5889-5892.
57. Caravan P, Greenfield MT, Li X, et al. The Gd(3+) complex of a fatty acid analogue of DOTP binds to multiple albumin sites with variable water relaxivities. Inorg Chem. 2001;40:6580-6587.
58. Ali MM, Woods M, Caravan P, et al. Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. Chem Eur J. 2008;14: 7250-7258.
59. Woods M, Caravan P, Geraldes CF, et al. The effect of the amide substituent on the biodistribution and tolerance of lanthanide(III) DOTA-tetraamide derivatives. Invest Radiol. 2008;43:861-870.
60. Jacques V, Dumas S, Sun WC, et al. High relaxivity MRI contrast agents part 2: optimization of inner and second-sphere relaxivity. Invest Radiol. 2010;45:613-624.